Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

被引:419
作者
Ochsenbein, AF
Sierro, S
Odermatt, B
Pericin, M
Karrer, U
Hermans, IF
Hemmi, S
Hengartner, H
Zinkernagel, RM [1 ]
机构
[1] Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland
[3] Malaghan Inst Med Res, Wellington, New Zealand
关键词
D O I
10.1038/35082583
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The vertebrate immune system has evolved to protect against infections that threaten survival before reproduction. Clinically manifest tumours mostly arise after the reproductive years and somatic mutations allow even otherwise antigenic tumours to evade the attention of the immune system(1-3). Moreover, the lack of immunological co-stimulatory molecules on solid tumours could result in T-cell tolerance(4-8); that is, the failure of T cells to respond. However, this may not generally apply(9,10). Here we report several important findings regarding the immune response to tumours, on the basis of studies of several tumour types. First, tumour-specific induction of protective cytotoxic T cells (CTLs) depends on sufficient tumour cells reaching secondary lymphatic organs early and for a long enough duration. Second, diffusely invading systemic tumours delete CTLs. Third, tumours that stay strictly outside secondary lymphatic organs, or that are within these organs but separated from T cells by barriers, are ignored by T cells but do not delete them. Fourth, co-stimulatory molecules on tumour cells do not influence CTL priming but enhance primed CTL responses in peripheral solid tumours. Last, cross priming of CTLs by tumour antigens, mediated by major histocompatibility complex (MHC) class I molecules of antigen-presenting host cells, is inefficient and not protective. These rules of T-cell induction and maintenance not only change previous views but also rationales for anti-tumour immunotherapy(1,2).
引用
收藏
页码:1058 / 1064
页数:7
相关论文
共 31 条
  • [1] CROSS-PRIMING FOR A SECONDARY CYTOTOXIC RESPONSE TO MINOR H-ANTIGENS WITH H-2 CONGENIC CELLS WHICH DO NOT CROSS-REACT IN CYTOTOXIC ASSAY
    BEVAN, MJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) : 1283 - 1288
  • [2] BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
  • [3] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun, S
    Pantel, K
    Muller, P
    Janni, W
    Hepp, F
    Kentenich, CRM
    Gastroph, S
    Wischnik, A
    Dimpfl, T
    Kindermann, G
    Riethmuller, G
    Schlimok, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) : 525 - 533
  • [4] Cross-presentation: A general mechanism for CTL immunity and tolerance
    Carbone, FR
    Kurts, C
    Bennett, SRM
    Miller, JFAP
    Heath, WR
    [J]. IMMUNOLOGY TODAY, 1998, 19 (08): : 368 - 373
  • [5] CHEN YM, 1993, MOL CRYST LIQ CRYS B, V4, P71
  • [6] HAHN H, 1981, REV INFECT DIS, V3, P1221
  • [7] MICE EXPRESSING BOTH B7-1 AND VIRAL GLYCOPROTEIN ON PANCREATIC BETA-CELLS ALONG WITH GLYCOPROTEIN-SPECIFIC TRANSGENIC T-CELLS DEVELOP DIABETES DUE TO A BREAKDOWN OF T-LYMPHOCYTE UNRESPONSIVENESS
    HARLAN, DM
    HENGARTNER, H
    HUANG, ML
    KANG, YH
    ABE, R
    MOREADITH, RW
    PIRCHER, H
    GRAY, GS
    OHASHI, PS
    FREEMAN, GJ
    NADLER, LM
    JUNE, CH
    AICHELE, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) : 3137 - 3141
  • [8] CAN CO-STIMULATED TUMOR-IMMUNITY BE THERAPEUTICALLY EFFICACIOUS
    HELLSTROM, KE
    HELLSTROM, I
    CHEN, LP
    [J]. IMMUNOLOGICAL REVIEWS, 1995, 145 : 123 - 145
  • [9] Hermans IF, 1998, CANCER RES, V58, P3909
  • [10] ROLE OF BONE-MARROW-DERIVED CELLS IN PRESENTING MHC CLASS I-RESTRICTED TUMOR-ANTIGENS
    HUANG, AYC
    GOLUMBEK, P
    AHMADZADEH, M
    JAFFEE, E
    PARDOLL, D
    LEVITSKY, H
    [J]. SCIENCE, 1994, 264 (5161) : 961 - 965